Phase III ATLAS Trial of Carfilzomib, Lenalidomide, and Dexamethasone vs Lenalidomide Alone as Maintenance After ASCT in Patients With NDMM

Experts highlight key studies being presented at the 2022 ASH Annual Meeting in this commentary from Clinical Care Options (CCO)

Catherine M. Broome, MD John M. Burke, MD Corey Cutler, MD, MPH, FRCPC David Dingli, MD, PhD Amir T. Fathi, MD Shaji K. Kumar, MD Sagar Lonial, MD Peter Martin, MD Marshall Mazepa, MD Srdan Verstovsek, MD, PhD Eunice S. Wang, MD Allison Wheeler, MD, MSCI Amer Zeidan, MBBS, MPH Released: December 7, 2022

Webcast from a live expert roundtable on practice-changing guideline updates for AML, from Clinical Care Options (CCO)

Adolfo de la Fuente Burguera, MD
Program Director Claudio Cerchione, MD, PhD Naval G. Daver, MD Pau Montesinos, MD, PhD Eytan M. Stein, MD Released: December 1, 2022

Webcast from a live expert roundtable on practice-changing guideline updates for AML, from Clinical Care Options (CCO)

Claudio Cerchione, MD, PhD
Program Director Naval G. Daver, MD Adolfo de la Fuente Burguera, MD Courtney DiNardo, MD, MSCE Giovanni Martinelli, MD Released: November 30, 2022

Downloadable PDF resource as a helpful guide for the differences between covalent and emerging non-covalent BTK inhibitors in MCL, from Clinical Care Options (CCO)